title: Pulmonary beta adrenoceptor density in arrhythmogenic right ventricular cardiomyopathy and idiopathic tachycardia.
abstract: OBJECTIVE
  In recent in vivo studies using positron emission tomography (PET) our group demonstrated that the myocardial beta adrenoceptor (betaAR) density is reduced in arrhythmogenic right ventricular cardiomyopathy (ARVC) and idiopathic right ventricular outflow tract tachycardia (RVO-VT) associated with an increased presynaptic catecholamine washout. It was hypothesised that the reduction of myocardial betaAR density is secondary to an increase of local catecholamines in the myocardium resulting from the presynaptic dysfunction since circulating plasma catecholamines were demonstrated to be unchanged in these conditions. To further prove this hypothesis of an organ-limited adrenergic nervous dysfunction of the heart, this study aimed to investigate betaAR density in another thoracic organ, the lung.
  
  
  METHODS
  Pulmonary and myocardial betaAR density was measured in 7 ARVC patients, 8 RVO-VT patients and in a group of healthy controls (n = 13) using the non-selective beta-blocker [11C]-CGP 12177 and PET.
  
  
  RESULTS
  Pulmonary betaAR density was similar in controls (12.4 +/- 1.7 pmol/g tissue), ARVC (11.6 +/- 1.7 pmol/g tissue, p = ns) and RVO-VT (12.8 +/- 2.0 pmol/g tissue, p = ns), whereas myocardial betaAR density was significantly reduced in ARVC (6.3 +/- 1.1 pmol/g tissue, p = 0.006) and RVO-VT (6.8 +/- 1.2 pmol/g tissue, p=0.02) as compared to controls (8.8+/-1.5 pmol/g tissue).
  
  
  CONCLUSIONS
  The unchanged pulmonary betaAR density in the presence of a previously described significant reduction in myocardial betaAR density in the same patient principally supports our pathophysiological hypothesis that the myocardial betaAR density may be reduced in ARVC and RVO-VT because of an increase in local synaptic catecholamine levels due to an organ-limited presynaptic adrenergic dysfunction of the heart. Since in the present study only pulmonary betaAR density was measured, future functional studies excluding pulmonary betaAR desensitisation are required to finally prove the unchanged pulmonary sympathetic innervation in ARVC and RVO-VT.
authors.affiliation: Department of Nuclear Medicine, Münster University, Germany. schafmi@uni-muenster.de
authors.forename: M A
authors.initials: MA
authors.lastname: Schäfers
authors.forename: T
authors.initials: T
authors.lastname: Wichter
authors.forename: K P
authors.initials: KP
authors.lastname: Schäfers
authors.forename: S
authors.initials: S
authors.lastname: Rahman
authors.forename: C G
authors.initials: CG
authors.lastname: Rhodes
authors.forename: A A
authors.initials: AA
authors.lastname: Lammertsma
authors.forename: H
authors.initials: H
authors.lastname: Lerch
authors.forename: M
authors.initials: M
authors.lastname: Knickmeier
authors.forename: F
authors.initials: F
authors.lastname: Hermansen
authors.forename: O
authors.initials: O
authors.lastname: Schober
authors.forename: P G
authors.initials: PG
authors.lastname: Camici
authors.forename: G
authors.initials: G
authors.lastname: Breithardt
mesh_terms: D000328:Adult; D001145:Arrhythmias, Cardiac / Q000209:etiology*; D009202:Cardiomyopathies / Q000150:complications* / Q000378:metabolism* / Q000503:physiopathology; D003326:Coronary Circulation; D005260:Female; D006352:Heart Ventricles; D006801:Humans; D008168:Lung / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D013610:Tachycardia / Q000378:metabolism*; D014018:Tissue Distribution; D016278:Ventricular Function, Right